<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37449199</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Case Report: Real NPSLE? A patient with systemic sclerosis overlapping systemic lupus erythematosus presenting as epilepsy.</ArticleTitle><Pagination><StartPage>1185501</StartPage><MedlinePgn>1185501</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1185501</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1185501</ELocationID><Abstract><AbstractText>Neuropsychiatric systemic lupus erythematosus (NPSLE) is the diagnosis that rheumatologists most often need to consider when a patient with lupus presents with neurologic symptoms. However, neurological involvement is rare in systemic sclerosis (SSc), and high doses of steroids tend to trigger scleroderma renal crisis (SRC). When a patient with SSc overlapping SLE presents with epilepsy and renal crisis, the exact diagnosis and whether to initiate high-dose glucocorticoid therapy are questions to ponder. Here, we report a patient with overlap syndrome (SSc overlapping SLE), who developed CNS symptoms, and improved after treatment against SRC after excluding NPSLE. We report this case with the aim of arousing the attention of rheumatologists to SSc and SRC-related encephalopathy when SSc was overlapped with SLE.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Zhang, Wu, Xue and Liu.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jialin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Teaching and Research, Jiande First People's Hospital, Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xiaodong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020945" MajorTopicYN="Y">Lupus Vasculitis, Central Nervous System</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012595" MajorTopicYN="Y">Scleroderma, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012594" MajorTopicYN="Y">Scleroderma, Localized</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="Y">Epilepsy</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">glucocorticoid</Keyword><Keyword MajorTopicYN="N">neuropsychiatric systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">rheumatic immune diseases</Keyword><Keyword MajorTopicYN="N">scleroderma renal crisis</Keyword><Keyword MajorTopicYN="N">systemic sclerosis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>14</Day><Hour>13</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>14</Day><Hour>3</Hour><Minute>59</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37449199</ArticleId><ArticleId IdType="pmc">PMC10336214</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1185501</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cole A, Ong VH, Denton CP. Renal disease and systemic sclerosis: an update on scleroderma renal crisis. Clin Rev Allergy Immunol (2022). doi: 10.1007/s12016-022-08945-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-022-08945-x</ArticleId><ArticleId IdType="pmc">PMC10167155</ArticleId><ArticleId IdType="pubmed">35648373</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao DL, Yang YL, Zhou LM, Liu QH, Liu R, Xu K, et al. . Systemic lupus erythematosus complicated with reversible posterior encephalopathy syndrome: a case report. J Int Med Res (2021) 49(7):3000605211029766. doi: 10.1177/03000605211029766</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/03000605211029766</ArticleId><ArticleId IdType="pmc">PMC8326631</ArticleId><ArticleId IdType="pubmed">34334006</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdez-Lopez M, Aguirre-Aguilar E, Valdes-Ferrer SI, Martinez-Carrillo FM, Arauz A, Barrera-Vargas A, et al. . Posterior reversible encephalopathy syndrome: a neuropsychiatric manifestation of systemic lupus erythematosus. Autoimmun Rev (2021) 20(2):102739. doi: 10.1016/j.autrev.2020.102739</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102739</ArticleId><ArticleId IdType="pubmed">33326853</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>